DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mesna (Mesna) - Mucosal Inflammation - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Mucosal Inflammation (23)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Mesna where reactions include mucosal inflammation. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-18

Patient: female, weighing 13.1 kg (28.8 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
    Indication: Sarcoma Metastatic

Vinorelbine Tartrate
    Dosage: last dose prior to sae:20/jun/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Doxorubicin Hydrochloride
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Cyclophosphamide
    Dosage: last dose prior to sae 23/jun/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Fluconazole; Levomepromazine; Cotrim; Docusate; Ondansetron; Gentamicin; Morphine; Moviprep; Neupogen; Neupogen; Dihydrocodeine Bitartrate INJ; Acetaminophen; Ondansetron; Docusate; Docusate; Piperacillin and Tazobactam; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-13

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine and Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Vinorelbine Tartrate
    Dosage: last dose prior to sae:20/jun/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Cyclophosphamide
    Dosage: last dose prior to sae 23/jun/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Ondansetron; Ondansetron; Gentamicin; Moviprep; Moviprep; Levomepromazine; Moviprep; Docusate; Cotrim; Docusate; Neupogen; Acetaminophen; Levomepromazine; Neupogen; Ondansetron; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Docusate; Morphine; Emollient Cream (Unk Ingredients)



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-06

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Cyclophosphamide
    Dosage: last dose prior to sae 23/jun/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vinorelbine Tartrate
    Dosage: last dose prior to sae:20/jun/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 20/jun/2012
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Levomepromazine; Docusate; Piperacillin and Tazobactam; Cotrim; Gentamicin; Ondansetron; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Ondansetron; Docusate; Moviprep; Neupogen; Acetaminophen; Levomepromazine; Moviprep; Docusate



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-07-02

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Vinorelbine Tartrate
    Dosage: last dose prior to sae 08/may/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Cyclophosphamide
    Dosage: last dose prior to sae 06/06/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 21/05/2012
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Levomepromazine; Moviprep; Moviprep; Cotrim; Morphine; Docusate; Docusate; Gentamicin; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Piperacillin and Tazobactam; Ondansetron; Neupogen; Dihydrocodeine Bitartrate INJ; Docusate; Neupogen



Possible Mesna side effects in

Reported by a health professional (non-physician/pharmacist) from Croatia (Local Name: Hrvatska) on 2012-06-12

Patient:

Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Condition Aggravated, Febrile Neutropenia

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: on day 1 with folinic acid rescue
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 with folinic acid rescue
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4, 5
    Indication: Burkitt's Leukaemia

Doxorubicin HCL
    Dosage: on days 4, 5
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: on days 1-5
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: days 4, 5
    Indication: Burkitt's Leukaemia

Leucovorin Calcium
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: on days 1-5
    Indication: Burkitt's Leukaemia

Prednisone TAB
    Dosage: days 1-5
    Indication: Burkitt's Leukaemia

Dexamethasone
    Dosage: on days 1-5
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: days 4, 5
    Indication: Burkitt's Lymphoma

Rituximab
    Indication: Burkitt's Leukaemia

Radiation Therapy NOS
    Dosage: 30-36 gy
    Indication: Burkitt's Leukaemia

Doxorubicin HCL
    Dosage: on days 4, 5
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: days 1-5
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Prophylaxis

Methylprednisolone
    Indication: Prophylaxis

Rituximab
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4, 5
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5
    Indication: Burkitt's Leukaemia

Leucovorin Calcium
    Indication: Burkitt's Leukaemia

Radiation Therapy NOS
    Dosage: 30-36 gy
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Prophylaxis

Mesna
    Dosage: on days 1-5
    Indication: Burkitt's Leukaemia

Mesna
    Dosage: on days 1-5
    Indication: Burkitt's Lymphoma

Other drugs received by patient: Blood Products; Acyclovir; Antibiotics; Neupogen



Possible Mesna side effects in female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-06-06

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Fungaemia, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Dosage: dadys 1 and 2
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Mesna
    Start date: 2011-09-21

Mesna

Mesna
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Cyclophosphamide
    Dosage: 11 mg
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Doxorubicin HCL
    Dosage: days 1 and 2
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Dactinomycin
    Dosage: day 1 of cycle
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Vincristine
    Dosage: days 1, 8 and 15 of cycle
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Bevacizumab
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Navelbine
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Other drugs received by patient: Ondansetron; Ondansetron; Levomepromazine; Docusate; Gentamycin Sulfate; Piperacillin and Tazobactam; Ondansetron; Neupogen; Levomepromazine; Docusate; Fluconazole; Docusate; Dihydrocodeine Bitartrate INJ; Ondansetron; Movicol / 01625101 /; Movicol / 01625101 /; Neupogen; Acetaminophen; Morphine; Movicol / 01625101 /; Cotrim



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2012-05-29

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Vinorelbine Tartrate
    Dosage: last dose prior to sae 08/may/2012
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 08/jul/2012
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Cyclophosphamide
    Dosage: last dose prior to sae 11/may/2012
    Administration route: Oral
    Indication: Rhabdomyosarcoma
    Start date: 2012-03-01

Other drugs received by patient: Fluconazole; Acetaminophen; Docusate; Emollient Cream (Unk Ingredients); Ondansetron; Ondansetron; Docusate; Morphine; Moviprep; Moviprep; Neupogen; Gentamicin; Moviprep; Ondansetron; Levomepromazine; Cotrim; Neupogen; Ondansetron; Levomepromazine; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Docusate



Possible Mesna side effects in 16 year old female

Reported by a health professional (non-physician/pharmacist) from France on 2012-03-23

Patient: 16 year old female

Reactions: Mucosal Inflammation, Dermatitis Bullous

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cytarabine
    Dosage: 30 mg, single
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-01-21
    End date: 2012-01-21

Methotrexate
    Dosage: 8220 mg, single
    Start date: 2012-01-20
    End date: 2012-01-20

Methotrexate
    Dosage: 12 mg, single
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-01-21
    End date: 2012-01-21

Cerubidine
    Dosage: 57 mg, 1x/day
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-01-24
    End date: 2012-01-24

Hydrocortisone
    Dosage: 15 mg, single
    Start date: 2012-01-26
    End date: 2012-01-26

Mesna
    Dosage: 330 mg, 1x/day
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-01-20
    End date: 2012-01-24

Cytarabine
    Dosage: 30 mg, single
    Start date: 2012-01-26
    End date: 2012-01-26

Hydrocortisone
    Dosage: 15 mg, single
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-01-21
    End date: 2012-01-21

Methotrexate
    Dosage: 12 mg, 1x/day
    Start date: 2012-01-26
    End date: 2012-01-26

Ifosfamide
    Dosage: 656 mg, 1x/day
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2012-01-20
    End date: 2012-01-24

Eldisine
    Dosage: 4 mg, single
    Start date: 2012-01-20
    End date: 2012-01-20

Other drugs received by patient: Furosemide; Calcium Levofolinate



Possible Mesna side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-13

Patient:

Reactions: Stomatitis, Haemoglobin Abnormal, Febrile Neutropenia, Platelet Disorder, Mucosal Inflammation, Diarrhoea, Colitis, Enteritis, Granulocytes Abnormal, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Neuroblastoma

Topotecan
    Dosage: 0.04 mg/kg/day
    Indication: Neuroblastoma

Etoposide
    Dosage: 6.67 mg/kg/day

Vincristine
    Dosage: 0.22 mg/kg/day

Cyclophosphamide
    Dosage: 70 mg/kg/day

Doxorubicin HCL

Cyclophosphamide
    Dosage: 13.3 mg/kg/day

Cyclophosphamide

Etoposide
    Dosage: 6.67 mg/kg/day

Vincristine
    Dosage: 0.22 mg/kg/day
    Indication: Neuroblastoma

Vincristine
    Dosage: 0.22 mg/kg/day

Cyclophosphamide
    Dosage: 70 mg/kg/day

Cyclophosphamide

Topotecan
    Dosage: 0.04 mg/kg/day

Cisplatin
    Dosage: 1.66 mg/kg/day

Mesna
    Dosage: 14 mg/kg/day

Cyclophosphamide
    Dosage: 70 mg/kg/day

Cyclophosphamide

Topotecan
    Dosage: 0.04 mg/kg/day

Cisplatin
    Dosage: 1.66 mg/kg/day

Vincristine
    Dosage: 0.22 mg/kg/day

Vincristine
    Dosage: 0.22 mg/kg/day

Neupogen
    Indication: Neutrophil Count

Cyclophosphamide
    Dosage: 70 mg/kg/day

Topotecan
    Dosage: 0.04 mg/kg/day

Mesna
    Dosage: 14 mg/kg/day

Mesna
    Dosage: 14 mg/kg/day

Mesna
    Dosage: 14 mg/kg/day

Doxorubicin HCL
    Dosage: 0.83 mg/kg/day
    Indication: Neuroblastoma

Doxorubicin HCL

Topotecan
    Dosage: 0.04 mg/kg/day

Cisplatin
    Dosage: 1.66 mg/kg/day
    Indication: Neuroblastoma

Cisplatin
    Dosage: 1.66 mg/kg/day

Etoposide
    Dosage: 6.67 mg/kg/day

Cyclophosphamide
    Dosage: 70 mg/kg/day

Doxorubicin HCL

Cyclophosphamide

Cisplatin

Cisplatin

Etoposide
    Dosage: 6.67 mg/kg/day
    Indication: Neuroblastoma

Etoposide
    Dosage: 6.67 mg/kg/day

Etoposide
    Dosage: 6.67 mg/kg/day

Mesna
    Dosage: 14 mg/kg/day
    Indication: Neuroblastoma

Mesna
    Dosage: 14 mg/kg/day

Vincristine
    Dosage: 0.22 mg/kg/day

Cyclophosphamide
    Dosage: 70 mg/kg/day

Doxorubicin HCL

Doxorubicin HCL

Topotecan
    Dosage: 0.04 mg/kg/day



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-02-14

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Other drugs received by patient: Ondansetron; Ondansetron; Fluconazole; Levomepromazine; Docusate; Docusate; Morphine; Neupogen; Emollient Cream (Unk Ingredients); Levomepromazine; Docusate; Neupogen; Ondansetron; Moviprep; Moviprep; Piperacillin and Tazobactam; Ondansetron; Paracetamol; Cotrim; Gentamicin; Dihydrocodeine Bitartrate INJ



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2012-01-18

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Other drugs received by patient: Acetaminophen; Ondansetron; Moviprep; Neupogen; Levomepromazine; Levomepromazine; Gentamicin; Emollient Cream (Unk Ingredients); Docusate; Piperacillin and Tazobactam; Morphine; Ondansetron; Neupogen; Ondansetron; Docusate; Moviprep; Ondansetron; Fluconazole; Docusate; Cotrim; Dihydrocodeine Bitartrate INJ



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2012-01-12

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, RED Blood Cell Count Decreased, Febrile Neutropenia, Platelet Count Decreased, Blood Sodium Decreased, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin Hydrochloride
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Levomepromazine; Levomepromazine; Docusate; Piperacillin and Tazobactam; Moviprep; Ondansetron; Neupogen; Neupogen; Cotrim; Ondansetron; Docusate; Docusate; Gentamicin; Dihydrocodeine Bitartrate INJ; Ondansetron; Fluconazole; Morphine; Acetaminophen; Ondansetron; Moviprep; Emollient Cream (Unk Ingredients)



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2012-01-10

Patient: female, weighing 12.9 kg (28.4 pounds)

Reactions: Haemoglobin Decreased, Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Blood Creatinine Increased, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Morphine; Moviprep; Ondansetron; Cotrim; Moviprep; Emollient Cream (Unk Ingredients); Dihydrocodeine Bitartrate INJ; Acetaminophen; Piperacillin and Tazobactam; Ondansetron; Fluconazole; Neupogen; Ondansetron; Docusate; Docusate; Neupogen; Ondansetron; Levomepromazine; Levomepromazine; Docusate; Gentamicin



Possible Mesna side effects in 32 month old female

Reported by a consumer/non-health professional from United Kingdom on 2011-12-12

Patient: 32 month old female, weighing 12.0 kg (26.4 pounds)

Reactions: Fungaemia, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Start date: 2011-07-12

Ifosfamide
    Start date: 2011-07-12

Mesna
    Start date: 2011-07-12

Vincristine Sulfate
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Mesna
    Start date: 2011-07-12

Dactinomycin
    Start date: 2011-07-12

Mesna
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Ifosfamide
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Bevacizumab
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Doxorubicin HCL
    Start date: 2011-07-12

Dactinomycin
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Vincristine Sulfate
    Start date: 2011-07-12

Doxorubicin HCL
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Dactinomycin
    Start date: 2011-07-12

Mesna
    Start date: 2011-07-12

Other drugs received by patient: Ondansetron; Acetaminophen; Levomepromazine; Docusate; Moviprep; Fluconazole; Emollients and Protectives; Moviprep; Ondansetron; Cotrim



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2011-12-08

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Other drugs received by patient: Acetaminophen; Cotrim; Moviprep; Docusate; Piperacillin and Tazobactam; Dihydrocodeine Bitartrate INJ; Morphine; Gentamicin; Neupogen; Emollient Cream (Unk Ingredients); Docusate; Neupogen; Ondansetron; Fluconazole; Levomepromazine; Levomepromazine; Ondansetron; Ondansetron; Ondansetron; Moviprep



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2011-12-07

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: date of last dose prior to sae: 21 sep 2011

Dactinomycin
    Dosage: dosage: 1-5 mg/m2, day 1, date of last dose prior to sae: 23 nov 2011
    Start date: 2011-07-12

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 24 nov 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 23 nov 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Fluconazole; Piperacillin and Tazobactam; Ondansetron HCL; Ondansetron HCL; Moviprep; Ondansetron HCL; Docusate; Neupogen; Emollient Cream (Unk Ingredients); Acetaminophen; Levomepromazine; Levomepromazine; Cotrim; Ondansetron HCL; Docusate; Moviprep; Dihydrocodeine Bitartrate INJ; Gentamicin; Morphine; Neupogen



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-12-05

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Acetaminophen; Emollient Cream (Unk Ingredients); Cotrim; Piperacillin and Tazobactam; Moviprep; Levomepromazine; Docusate; Gentamicin; Neupogen; Fluconazole; Ondansetron; Morphine; Ondansetron; Moviprep



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-11-29

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior to sae: 30 august 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Neupogen; Ondansetron; Fluconazole; Piperacillin and Tazobactam; Morphine; Moviprep; Emollient Cream (Unk Ingredients); Paracetamol; Cotrim; Gentamicin; Moviprep; Docusate; Levomepromazine



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-11-14

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Other drugs received by patient: Ondansetron; Docusate; Moviprep; Acetaminophen; Cotrim; Morphine; Emollient Cream (Unk Ingredients); Levomepromazine; Piperacillin and Tazobactam; Fluconazole; Gentamicin; Ondansetron; Moviprep; Neupogen



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-11-11

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Mucosal Inflammation, Candida Test Positive, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: date of last dose prior to onset of sae: 11 oct 2011

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cyclelast doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Gentamicin; Levomepromazine; Moviprep; Emollient Cream (Unk Ingredients); Acetaminophen; Ondansetron; Moviprep; Fluconazole; Cotrim; Ondansetron; Docusate; Morphine; Neupogen; Piperacillin and Tazobactam



Possible Mesna side effects in 32 month old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-27

Patient: 32 month old female, weighing 11.0 kg (24.2 pounds)

Reactions: Fungaemia, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Ifosfamide
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Mesna
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Doxorubicin HCL
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Ifosfamide
    Start date: 2011-07-12

Vincristine Sulfate
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Dactinomycin
    Start date: 2011-07-12

Mesna
    Start date: 2011-07-12

Mesna
    Start date: 2011-07-12

Doxorubicin HCL
    Start date: 2011-07-12

Bevacizumab
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Dactinomycin
    Indication: Sarcoma Metastatic
    Start date: 2011-07-12

Other drugs received by patient: Ondansetron; Levomepromazine; Cotrim; Acetaminophen; Moviprep; Moviprep; Docusate; Fluconazole



Possible Mesna side effects in female

Reported by a physician from United Kingdom on 2011-10-18

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cycle last doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin HCL
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Acetaminophen; Cotrim; Neupogen; Levomepromazine; Ondansetron; Piperacillin and Tazobactam; Fluconazole; Gentamycin Sulfate; Ondansetron; Docusate; Morphine; Moviprep; Moviprep



Possible Mesna side effects in female

Reported by a individual with unspecified qualification from United Kingdom on 2011-10-05

Patient: female, weighing 12.7 kg (27.9 pounds)

Reactions: Candida Test Positive, Mucosal Inflammation, Febrile Neutropenia, Epistaxis

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Mesna
    Dosage: frequency: days 1 and 2 dosage form: 3600 mg/m2 last dose prior to sae was taken on 09 aug 2011
    Indication: Sarcoma Metastatic

Dactinomycin
    Dosage: frequency: day 1 of cycle dosage: 1.5 mg/m2 last dose prior to sae was taken on 30 aug 2011
    Indication: Sarcoma Metastatic

Vincristine
    Dosage: dosage cumm: 1.5 mg/m2, frequency days 1,8 and 15 of cycle last doseprior to sae: 30 aug 2011
    Indication: Sarcoma Metastatic

Ifosfamide
    Dosage: frequency: days 1 and 2. dosage form:3g/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Doxorubicin Hydrochloride
    Dosage: frequency: days 1 and 2 dosage: 30 mg/m2 last dose prior to sae was taken on 31 aug 2011
    Indication: Sarcoma Metastatic

Mesna
    Dosage: frequency: od, dosage form: 3600 mg/m2

Avastin
    Dosage: frequency: day 1, last dose prior tosae: 30 august 2011
    Indication: Sarcoma Metastatic

Other drugs received by patient: Gentamycin Sulfate; Piperacillin and Tazobactam; Ondansetron; Ondansetron; Morphine; Acetaminophen; Fluconazole; Levomepromazine; Cotrim; Moviprep; Docusate; Moviprep; Neupogen

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017